University of Pittsburgh Medical Center: Immunotherapy Drug Pembrolizumab Improves Outcomes for Patients With Soft Tissue Sarcoma
November 13, 2024
November 13, 2024
PITTSBURGH, Pennsylvania, Nov. 13 (TNSres) -- The University of Pittsburgh Medical Center issued the following news release:
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University and Princess Margaret Cancer Centre, University Heal . . .
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University and Princess Margaret Cancer Centre, University Heal . . .